Ai2 agrees Sauflon deal
MANCHESTER university medical coatings spin-out Ai2 has signed a development and licensing agreement with UK based Sauflon Pharmaceuticals.
Sauflon, based in Manchester, specialises in a variety of eye-related products and is interested in Ai2’s antibacterial peptide technology.
The contract will see Ai2’s peptides being developed for use in a number of Sauflon’s opthalmic products, including contact lenses and contact lens cleaning solutions.
Chief executive Jim McNairney said: “Concluding this first commercial deal from among Ai2’s various strategic development collaborations is a landmark moment in Ai2’s short history.
“Working with Sauflon will deliver a strong strategic partnership for Ai2 which will enable our anti-infectives technology to enter the growing ophthalmic products market.”
Medical technology investment specialist MTI Partners is the lead investor in Ai2.
